

# Recent advances in the diagnosis and treatment of diabetic cardiomyopathy

Gabriele Fragasso, Alberto Margonato

*Division of Cardiology, Heart Failure Unit, Hospital San Raffaele, Milan, Italy*

(Ital Heart J 2001; 2 (Suppl 3): 7S-11S)

© 2001 CEPI Srl

*Address:*

Dr. Alberto Margonato

*Divisione di Cardiologia  
Istituto Scientifico  
San Raffaele  
Via Olgettina, 60  
20132 Milano  
E-mail:  
insufficienza.cardiaca@  
hsr.it*

## Introduction

Cardiovascular disease is the major cause of morbidity and mortality in patients with diabetes. While it was once thought that ischemic heart disease was responsible for most of these adverse effects, recent data suggest that one of the major adverse complications of diabetes is the development of a specific diabetic cardiomyopathy, characterized by both diastolic and systolic left ventricular dysfunction. Indeed, a bulk of epidemiological, anatomical, experimental animal and human studies indicate the existence of a specific diabetic myocardial disease<sup>1</sup>, independent of coronary atherosclerosis. The risk of heart failure is grossly increased in diabetic patients<sup>2</sup>, as already evidenced by the Framingham Heart Study<sup>3</sup>. In this study, diabetic male patients had more than twice the incidence rate of heart failure compared to non-diabetic cohorts, while diabetic women showed a 5-fold increased risk. Thus, diabetes mellitus is closely linked to heart failure.

The purpose of the present article is to review the main epidemiologic, prognostic and therapeutic knowledge related to heart failure and diabetes.

## Anatomic and functional changes

Several studies have been dedicated to the evaluation of morphological changes in the diabetic heart<sup>4</sup>. Anatomic studies have shown that diabetic cardiomyopathy is mainly characterized by alterations in the microvasculature and myocardial interstitium<sup>5,6</sup>. In the initial stages of the disease, interstitial changes with preserved myocytes and microvascular morphology may

predominate and cause the observed reduction in myocardial compliance<sup>7</sup>. With disease progression, salient findings include left ventricular hypertrophy with perivascular, interstitial and replacement fibrosis, and accumulation of periodic acid-Schiff (PAS)-positive material. Arteriolar or capillary involvement typical of diabetic microangiopathy, including increased thickening of myocardial capillary-basement membrane and microaneurysms occurs later in association with more severe myocardial dysfunction<sup>8</sup>. These lesions are not characteristic for diabetes only and appear to be synergistic with structural changes usually observed in arterial hypertension. This fact might be particularly relevant in the light of the positive effects of antihypertensive therapy in diabetic patients observed in the UKPDS<sup>9</sup> and HOT<sup>10</sup> studies.

The above described pathological alterations are associated with a wide range of myocardial dysfunction states, ranging from asymptomatic diastolic dysfunction to overt systolic heart failure. Diminished left ventricular compliance in the presence of normal systolic function is usually the initial step<sup>11,12</sup>. Diastolic abnormalities occur in 27 to 69% of asymptomatic diabetic patients<sup>11,13,14</sup> and may often predict subsequent progression towards the development of frank heart failure<sup>11</sup>. Although diastolic abnormalities have been shown to occur early in the course of diabetes even in the presence of only mild microvascular complications<sup>11,14,15</sup>, small vessel coronary disease remains the culprit factor in the pathogenesis of diabetic cardiomyopathy. Interestingly, the combination of diastolic dysfunction<sup>16</sup> and alterations of glucose metabolism<sup>17,18</sup> is also observed in patients with both the metabolic and cardiac syn-

drome X<sup>19</sup> where, again, microvascular disease is likely to play a major role<sup>20</sup>.

Even in the absence of frank systolic dysfunction in resting conditions, several studies have shown a lower ejection fraction in response to dynamic exercise<sup>21-23</sup>, suggesting a decreased functional reserve in many asymptomatic patients with diabetes. However, even subclinical cardiomyopathy with reduced functional reserve may become clinically important in the context of uncontrolled arterial hypertension and/or the presence of myocardial ischemia. Indeed, diabetic patients experiencing myocardial infarction have a poorer prognosis compared to non-diabetics<sup>24</sup>, although infarct size is not larger<sup>25</sup>.

### Pathophysiology

The pathophysiology of diabetic cardiomyopathy remains largely unknown and several working hypotheses have been investigated. Contributing to its development is a shift in myosine isoenzyme content in favor of the least active V3 form<sup>26</sup>. Calcium homeostasis also appears defective. While calcium transport by the sarcolemmal and sarcoplasmic reticular calcium pumps are minimally affected by diabetes, significant impairment occurs in Na<sup>(+)</sup>-Ca<sup>2+</sup> exchanger activity. This defect limits the ability of the diabetic heart to extrude calcium, contributing to an elevation in (Ca<sup>2+</sup>)<sub>i</sub>. A decrease in Na<sup>+</sup>, K<sup>+</sup>-ATPase activity, which is known to increase (Ca<sup>2+</sup>)<sub>i</sub> secondary to a rise in (Na<sup>+</sup>)<sub>i</sub>, may also promote the accumulation of calcium by the diabetic cell<sup>26</sup>. It is very likely that these defects are related to aberrations of glucose and/or lipid metabolism which involve membrane changes, such as phosphatidylethanolamine N-methylation and protein phosphorylation which, in turn, determine myocyte metabolic dysfunction.

Adverse cardiac effects of diabetes could also be due to the following events. Carbohydrate and lipid metabolism alterations consequent to diabetes mellitus are closely linked to the accumulation of various acylcarnitine and coenzyme derivatives. Abnormally high amounts of metabolic intermediates could cause disturbances in calcium homeostasis which, in the long term, can eventually lead to cardiac dysfunction<sup>27</sup>. In this context, lowering raised plasma triglycerides and free fatty acid levels could therefore decrease the heart's reliance on fatty acids and overcome the fatty acid inhibition of myocardial glucose utilization. In fact, increased levels of citrate, produced by free fatty acid oxidation, inhibit phosphofructokinase, leading to decreased glycolysis and promoting glycogen synthesis. Impaired glucose oxidation also leads to lactic acid accumulation which further promotes the degradation of free fatty acids.

Finally, reduced myocardial blood flow has been clearly related to diabetes mellitus<sup>28</sup>, independently of

frank epicardial coronary disease and linked to impaired endothelial function<sup>29-31</sup>. Acute hyperglycemia may further impair endothelial-derived vasodilation<sup>32</sup>. In fact, the inability to increase myocardial blood flow appears independently related to long-term blood glucose control<sup>33</sup>, indicating that hyperglycemia by itself is of considerable importance for the impaired vascular function. Hyperinsulinemia, by increasing the production of endothelial factors such as endothelins<sup>34</sup>, will also probably adversely affect the evolution of cardiovascular disease. In the long term, impaired coronary flow reserve, in the presence of the above described metabolic alterations, might well determine and aggravate a cardiomyopathic process.

In summary, the pathophysiological mechanisms at the base of diabetic cardiomyopathy are likely to be multifactorial, including metabolic and vascular components. This indicates that strict glycemic control and increased free fatty acid oxidation are likely to be beneficial.

### Diagnosis

Clinical and instrumental procedures for the diagnosis of diabetic cardiomyopathy do not differ from those adopted for the diagnosis of other forms of cardiomyopathies. Routine electrocardiography and, when necessary, echocardiography remain the gold standard tools. Considering the high prevalence of cardiovascular complications, diabetic patients are regularly prescribed cardiac screening tests that will eventually unmask concomitant cardiac involvement. Nevertheless, in recent years additional tests have been proposed in order to improve the diagnostic accuracy of routine cardiac testing and to detect early diabetic cardiomyopathy. Among the others, tests aimed at evaluating whether sympathetic neuropathy, as assessed by iodine-123-metaiodobenzylguanidine myocardial scintigraphy, could predict subsequent cardiac involvement in asymptomatic patients are still under investigation<sup>35,36</sup>.

New echocardiographic methods have also been implemented, such as echocardiographic myocardial texture analysis<sup>37</sup> and ultrasonic myocardial videodensitometric analysis<sup>38</sup>. Indeed, abnormally increased myocardial echodensity, possibly related to collagen deposition, can be detected in asymptomatic diabetic patients with normal rest function. Theoretically, this finding might be considered a very early preclinical alteration potentially related to subsequent development of diabetic cardiomyopathy.

Vectorcardiography has also been shown to potentially predict the occurrence of diabetic cardiomyopathy<sup>39</sup> and, finally, combined myocardial blood flow and glucose metabolism assessment by positron emission tomography has been proposed as a valuable test<sup>40</sup>. The introduction of genetic diagnosis in the near future will

certainly provide the definitive answer to the problem of early detection of diabetic cardiomyopathy<sup>41</sup>. However, despite promising animal studies<sup>42</sup>, a specific diagnostic test applicable to humans has yet to be defined.

## Therapy

A meticulous metabolic control in diabetic patients will definitely delay the occurrence of cardiovascular complications and improve the prognosis once they have occurred. The specific cardiological therapeutic approach to diabetic cardiomyopathy does not significantly differ from that adopted for other forms of cardiomyopathies. The established use of ACE-inhibitors and beta-blockers in patients with heart failure also applies to diabetic patients. Recent data suggest that the beneficial effects of ACE-inhibition in heart failure patients are even greater in diabetic people<sup>43-45</sup>. The observed super benefits of ACE-inhibitor therapy in diabetic patients are likely due to a variety of mechanisms, since they are greater than those attributable to the decrease in blood pressure<sup>46</sup> and are probably related to specific vasculoprotective and renoprotective effects of ACE-inhibition, mediated by a decrease in angiotensin 2 levels and an increase in bradykinins<sup>47</sup>.

Diabetic patients have been traditionally considered less suitable than non diabetic patients for beta-blocker therapy, because of the risk of worsened glucose and lipid metabolism and weakened reaction to potential hypoglycemia. Indeed, classical beta-1 selective beta-blockers reduce insulin sensitivity and impair lipid metabolism. These unfavorable effects are overcome by the introduction of beta-blockers with alpha-1 blocking properties, which have been shown to improve insulin sensitivity and glucose metabolism and should therefore be suitable for diabetic patients<sup>48-50</sup>. Therefore, in the light of the most recent trials of vasodilating beta-blockers in heart failure<sup>51,52</sup>, their use in diabetic patients is advocated. Nevertheless, prospective stratification of diabetic patients in large clinical trials would produce important insight into the specific value of beta-blockade in this group of heart failure patients<sup>53</sup>.

Finally, recent studies show that patients with advanced ischemic heart failure may benefit from treatment with trimetazidine, a piperazine derivative with fatty acid inhibition properties that is at present employed for the treatment of angina pectoris<sup>54</sup>. These ancillary properties of the molecule have been incidentally observed to be mainly operative in patients who, apart from ischemic cardiomyopathy, are also diabetic. The mechanism of action is related to the property of trimetazidine to facilitate myocardial utilization of glucose instead of free fatty acids which, in the context of malfunctioning myocardial cells, appear to be deleterious. Studies employing ranolazine, a similar drug<sup>55</sup>, have come to the same conclusions<sup>56</sup>. Interestingly,

compounds that stimulate pyruvate dehydrogenase activity thereby facilitating glucose oxidation and inhibiting free fatty acid oxidation, such as dichloroacetate, have been shown to improve left ventricular function in heart failure patients<sup>57</sup>. Further studies are in progress and, if the preliminary results will be confirmed, partial fatty acid inhibitors will open a new therapeutic strategy in the treatment of diabetic cardiomyopathy.

## Conclusions

Diabetes mellitus is becoming progressively common. Most diabetic patients will develop cardiovascular complications, of whom diabetic cardiomyopathy is one of the most frequent and insidious. The early detection of cardiomyopathy in diabetic patients should be actively sought by both cardiologists and diabetologists, aware of its high frequency rate. Apart from meticulous metabolic control of diabetes, cardiomyopathy should be aggressively treated with those drugs at present effectively employed for the treatment of heart failure. Future studies will indicate whether drugs directly affecting myocardial cell metabolism will have any role in the management of diabetic cardiomyopathy.

## References

- Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence of a distinct diabetic cardiomyopathy: the Framingham Heart Study. *Am J Cardiol* 1991; 68: 85-9.
- Coughlin SS, Pearle DL, Baughman KL, Wasserman A, Tefft MC. Diabetes mellitus and the risk of idiopathic dilated cardiomyopathy: the Washington, DC Dilated Cardiomyopathy Study. *Ann Epidemiol* 1994; 6: 67-74.
- Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974; 34: 29-34.
- Hardin N. The myocardial and vascular pathology of diabetic cardiomyopathy. *Coron Artery Dis* 1996; 7: 1337-44.
- Zarich S, Nesto R. Diabetic cardiomyopathy. *Am Heart J* 1989; 118: 1000-12.
- Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. *J Clin Invest* 1977; 60: 885-99.
- Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. *Prog Cardiovasc Dis* 1985; 27: 255-70.
- Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. *N Engl J Med* 1980; 302: 384-8.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; 317: 703-13.
- Hansson L, Zanchetti A, Carruthers SG, Dalh f B, Elmfeldt D, Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998; 351: 1755-62.
- Zarich SW, Arbuckle BE, Cohen LR, et al. Diastolic abnormalities in young asymptomatic diabetic patients assessed

- by pulsed Doppler echocardiography. *J Am Coll Cardiol* 1988; 12: 114-20.
12. Riggs TW, Transue D. Doppler echocardiographic evaluation of left ventricular diastolic dysfunction in adolescents with diabetes mellitus. *Am J Cardiol* 1990; 65: 899-902.
  13. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type 1 diabetic patients. *Diabetes Care* 1994; 17: 633-9.
  14. Paillole C, Dahan M, Payche F, et al. Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type 1 (insulin-dependent) diabetic patients. *Am J Cardiol* 1990; 64: 1010-6.
  15. Gøtzsche O, Darwish A, Hansen LP, Gøtzsche L. Abnormal left ventricular diastolic function during cold pressor test in uncomplicated insulin-dependent diabetes mellitus. *Clin Sci* 1995; 89: 461-5.
  16. Fragasso G, Chierchia S, Pizzetti G, et al. Impaired left ventricular filling dynamics in patients with angina pectoris and angiographically normal coronary arteries: effect of beta-adrenergic blockade. *Heart* 1997; 77: 32-9.
  17. Dean JD, Jones CJ, Hutchison SJ, Peters JR, Henderson AH. Hyperinsulinaemia and microvascular angina ("syndrome X"). *Lancet* 1991; 337: 456-7.
  18. Fragasso G, Chierchia SL, Rossetti E, Landoni C, Lucignani G, Fazio F. Abnormal myocardial glucose handling in patients with syndrome X: effect of beta-adrenergic blockade. *G Ital Cardiol* 1997; 27: 1113-20.
  19. Henderson AH. The two syndrome X. In: Kaski JC, ed. *Chest pain with normal coronary angiograms: pathogenesis, diagnosis and management*. Boston, MA: Kluwer Academic Publishers, 1999: 263-9.
  20. Cannon RO, Epstein SE. Microvascular angina as a cause of chest pain in patients with angiographically normal coronary arteries. *Am J Cardiol* 1988; 61: 1338-43.
  21. Mildenerger RR, Bar-Shlomo B, Druck MN, et al. Clinically unrecognized ventricular dysfunction in young diabetic patients. *J Am Coll Cardiol* 1984; 4: 234-8.
  22. Vered A, Battler A, Segal P, et al. Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). *Am J Cardiol* 1984; 54: 633-7.
  23. Margonato A, Gerundini P, Vicedomini G, Gilardi MC, Pozza G, Fazio F. Abnormal cardiovascular response to exercise in young asymptomatic diabetic patients with retinopathy. *Am Heart J* 1986; 112: 554-60.
  24. Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. *Am Heart J* 1984; 108: 31-7.
  25. Stone PH, Muller JE, Hartwell T, et al, for the MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and left ventricular dysfunction to the adverse prognosis. *J Am Coll Cardiol* 1989; 29: 49-57.
  26. Shaffer SW. Cardiomyopathy associated with non-insulin-dependent diabetes. *Mol Cell Biochem* 1991; 107: 1-20.
  27. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. *J Mol Cell Cardiol* 1995; 27: 169-79.
  28. Pitkanen OP, Nuutila P, Raitakari OP, et al. Coronary flow reserve is reduced in young men with insulin-dependent diabetes mellitus. *Diabetes* 1998; 47: 248-54.
  29. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. *Circulation* 1993; 88: 2510-6.
  30. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes mellitus. *J Clin Invest* 1992; 90: 2548-54.
  31. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus. *J Am Coll Cardiol* 1996; 27: 567-74.
  32. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Creager MA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation* 1998; 97: 1695-701.
  33. Youkoyama I, Momomura SI, Ohtake T, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 1997; 30: 1472-7.
  34. Piatti PM, Monti LD, Galli L, et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. *Metabolism* 2000; 49: 748-52.
  35. Scognamiglio R, Avogaro A, Casara D, et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 1998; 31: 404-12.
  36. Sugiyama T, Kurata C, Tawarahara K, Nakano T. Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus? *J Nucl Cardiol* 2000; 7: 562-8.
  37. Kerut EK, Given MB, McIlwain E, Allen G, Espinoza C, Giles TD. Echocardiographic texture analysis using the wavelet transform: differentiation of early muscle disease. *Ultrasound Med Biol* 2000; 26: 1445-53.
  38. Di Bello V, Giampietro O, Matteucci E, et al. Ultrasonic videodensitometric analysis in type 1 diabetic myocardium. *Coron Artery Dis* 1996; 7: 895-901.
  39. Edenbrandt L, Jakobsson A, Lindvall E, Bitzen PO, Pahlm O. Increased prevalence of large bites in 12-lead vectorcardiograms of diabetic patients. *J Electrocardiol* 1997; 30: 91-5.
  40. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. *Am J Cardiol* 1997; 80: 94A-101A.
  41. Zoneraich S. Unraveling the conundrums of the diabetic heart diagnosed in 1876: prelude to genetics. *Can J Cardiol* 1994; 10: 945-50.
  42. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta<sub>2</sub> isoform in myocardium causes cardiomyopathy. *Proc Natl Acad Sci USA* 1997; 94: 9320-5.
  43. Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. *Circulation* 1997; 96: 4239-45.
  44. Gustafsson I, Torp-Pedersen C, Køber L, et al. Effect of the angiotensin-converting enzyme inhibitor tandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. *J Am Coll Cardiol* 1999; 34: 83-9.
  45. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in patients with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet* 2000; 355: 253-9.
  46. Mancini GB, Stewart DJ. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding? *Can J Cardiol* 17: 15A-17A.
  47. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. *Circulation* 1994; 90: 2056-69.



48. Ehmer B, van der Does R, Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. *Drugs* 1988; 36 (Suppl 6): 136-40.
49. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. *J Hypertens* 1996; 14: 489-94.
50. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. *Ann Intern Med* 1997; 126: 955-9.
51. Packer M, Bristow MR, Cohn JN, et al. The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996; 334: 1349-55.
52. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; 353: 9-13.
53. Soläng L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart failure: further knowledge needed. *Eur Heart J* 1999; 20: 789-95.
54. Fragasso G, Piatti PM, Monti LD, et al. Myocardial, metabolic and endothelial effects of trimetazidine in diabetic patients with ischemic dilated cardiomyopathy. (abstr) *J Am Coll Cardiol* 2001; 37: 154A.
55. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. *Circulation* 1996; 93: 135-42.
56. Chaitman BR, Skettino S, DeQuattro V, et al. Improved exercise performance on ranolazine in patients with chronic angina and a history of heart failure: the MARISA trial. (abstr) *J Am Coll Cardiol* 2001; 37: 149A.
57. Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. *J Am Coll Cardiol* 1994; 23: 1617-24.